Gene therapy holds great promise for treating a multitude of inherited and acquired diseases
by delivering functional genes, comprising DNA or RNA, into targeted cells or tissues to elicit …

Polyethlyenimine (PEI) was introduced 1995 as a cationic polymer for nucleic acid delivery.
PEI and its derivatives are extensively used in basic research and as reference formulations …

microRNAs are small non-coding RNAs that regulate several genes post-transcriptionally by
complementarity pairing. Since discovery, they have been reported to be involved in a …

Small interfering RNA (siRNA) is a potential method of gene silencing to target specific
genes. Although the US Food and Drug Administration (FDA) has approved multiple siRNA …

Cellular metabolism is an intricate network satisfying bioenergetic and biosynthesis
requirements of cells. Relevant studies have been constantly making inroads in our …

Lipid nanoparticles (LNPs) are currently the most promising clinical nucleic acids drug
delivery vehicles. LNPs prevent the degradation of cargo nucleic acids during blood …

Lipid‐based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic
acid drug (NAD) delivery. Although their clinical applications have achieved success, the …

Nano-drug delivery strategies have been highlighted in cancer treatment, and much effort
has been made in the optimization of bioavailability, biocompatibility, pharmacokinetics …

Tumor vaccination is a promising approach for tumor immunotherapy because it presents
high specificity and few side effects. However, tumor vaccines that contain only a single …

For the longest time, the field of nucleic acid delivery has remained skeptical whether or not
polycationic drug carrier systems would ever make it into clinical practice. Yet, with the …